Clinical case 10
Stabilisation of primary progressive multiple sclerosis and marked functional improvement
man, 54 · Belgium
Patient record
- Patient
- man, 54
- Country
- Belgium
- Diagnosis
- multiple sclerosis, primary progressive course
- Main features before treatment
- no independent walking, marked weakness mainly in the left limbs, spasticity, reduced sensation, impaired coordination, cramps in the limbs, urinary retention
- Functional status
- wheelchair user, severely limited independent mobility
- Treatment given
- an individual autologous cell and neuroregenerative protocol
- Course after treatment
- stabilisation and an end to the previous deterioration, considerably reduced spasticity, increased strength in the left limbs, improved sensation and coordination, fewer cramps
History
The multiple sclerosis has followed a long progressive course. Disability had developed well before the patient came to us, and the formal diagnosis was made in 2016.
As the disease advanced, his motor capacity gradually declined. He lost the ability to walk unaided and came to use a wheelchair permanently.
Specialist neurological reports assessed the disease as primary progressive multiple sclerosis with a marked motor deficit. At one stage of follow-up the level of disability reached an EDSS of about 7.5.
The clinical picture was dominated by marked spasticity, weakness of the limbs, reduced sensation and a considerable restriction of voluntary motor activity.
In 2023 the patient had already undergone a course of cell therapy at another medical centre. Afterwards he noted an improvement in general wellbeing, but no marked recovery of strength in the limbs followed.
Before treatment
The patient's main problems were:
- inability to walk unaided
- marked weakness of the limbs, more noticeable on the left
- considerably increased muscle tone and spasticity
- reduced sensation
- impaired coordination of movement
- cramps in the limbs
- urinary retention
- severely limited independence in daily life
Before our programme the patient was continuing to notice a gradual deterioration in his neurological condition.
The main aims of treatment were to stabilise the progressive process, preserve the functional reserve that remained and improve motor and sensory capacity.
The programme
A personalised autologous cell and neuroregenerative programme was designed for the patient.
The protocol included:
- systemic therapy with mesenchymal stromal cells
- a neurally targeted component using neurally induced mesenchymal cells
- concentrated exosome therapy
- a combination of systemic and intrathecal approaches
The exact doses, the characteristics of the cell products and the sequence of procedures formed part of an individual internal protocol.
Course after treatment
After the programme the patient noted marked positive neurological change.
Disease stabilisation
One of the most important results was that the previous clinical progression of the disease stopped.
The patient no longer noticed the steady deterioration he had seen before treatment. Over the follow-up period his neurological status became considerably more stable.
Muscle tone
There was a marked reduction in spasticity and in the pathologically raised muscle tone.
His limbs became less stiff and movement freer and easier to direct.
Muscle strength
At the same time the patient noted increased strength in the limbs, particularly on the left, where the motor deficit had been most marked before treatment.
It is particularly significant that active strength increased against a background of reduced spasticity.
Sensation
Positive change in sensation also appeared.
The patient felt his limbs better, and his perception of movement and body position improved.
Coordination
Significant improvement in the coordination of movement was noted.
Voluntary movements became more precise, better coordinated and easier to control.
Cramps
After treatment the frequency and severity of cramps in the limbs also decreased, which further improved the patient's day-to-day condition.
Outcome
After the individual programme the most significant results were:
- the previous clinical progression of the disease stopped;
- the patient no longer noticed further deterioration
- spasticity decreased considerably
- the pathologically raised muscle tone fell
- strength increased, particularly in the left limbs;
- sensation improved
- coordination of movement improved considerably
- cramps decreased
- overall motor control improved
What mattered particularly in this case was the combination of stabilisation of a previously progressive condition with functional improvement at the same time.
After a long period of steady deterioration the patient not only stopped losing further function, but gained positive change in precisely the most troublesome areas – muscle strength, spasticity, sensation and coordination of movement.
This case is described from the patient's medical records and observation over the period after the programme. No personal data is published. The course of the disease and the response to treatment differ from patient to patient.